In Situ Formation of Er0.4Bi1.6O3 Protective Layer at Cobaltite Cathode/Y2O3–ZrO2 Electrolyte Interface under Solid Oxide Fuel Cell Operation Conditions

© Copyright 2018 American Chemical Society. Bismuth-based oxides exhibit outstanding oxygen ionic conductivity and fast oxygen surface kinetics and have shown great potential as a highly active component for electrode materials in solid oxide fuel cells (SOFCs). Herein, a Nb-doped La0.6Sr0.4Co0.2Fe0.7Nb0.1O3-d (LSCFNb) electrode with 40% Er0.4Bi1.6O3 (ESB) composite electrode was successfully fabricated by decoration method and directly assembled on barrier-layer-free yttrium-stabilized zirconia (YSZ) electrolyte cells, achieving a peak power density of 1.32 W cm-2 and excellent stability at 750 °C and 250 mA cm-2 for 100 h. ESB decoration also significantly reduces the activation energy from 214 kJ mol-1 for the O2 reduction on pristine LSCFNb electrode to 98 kJ mol-1. Further microstructural analysis reveals that there is a redistribution and migration of the ESB phase in the ESB-LSCFNb composite toward the YSZ electrolyte under the influence of cathodic polarization, forming a thin ESB layer at the cathode/YSZ electrolyte interface. The in situ formed ESB layer not only prevents the direct contact and subsequent reaction between segregated SrO and YSZ electrolytes, but also remarkably promotes the oxygen migration/diffusion at the interface for O2 reduction reaction, resulting in a remarkable increase in power output and a decrease in activation energy. The present study clearly demonstrated the in situ formation of a highly functional and active ESB protective layer at LSCFNb cobaltite cathode and YSZ electrolyte interface via ESB-decorated LSCFNb composite cathode under SOFC operation conditions

Uptake of evidence-based statin therapy among atrial fibrillation patients in China:a report from the CAFR (Chinese Atrial Fibrillation Registry) Study

Background:Atrial fibrillation (AF) is associated with increased incidence of cardiovascular disease, and hence, statin therapy is indicated in majority of AF patients.Methods and results:We analyzed data from the Chinese Atrial Fibrillation Registry (CAFR) involving 11,496 AF patients from 2011 to 2014. Practice patterns of statin therapy and factors associated with statin underuse were analyzed.Based on the 2013 ACC/AHA cholesterol management guidelines, statins should be recommended for 67.4% (7720/11,461) of AF participants in CAFR, but only 43.4% (3352/7720) with appropriate indications were taking statins. Statin underuse in AF patients was independently associated with male sex, tertiary hospital treatment, outpatient attendance, and absence of ‘high risk’ cardiovascular risk factors (overweight, diabetes, coronary heart disease, stroke/transient ischemic attack/peripheral embolism and hypertension).Conclusions:A high proportion of Chinese AF patients had indications for statin therapy. Evidence-based statin prescribing was suboptimal in this population. Greater efforts should be made to improve a holistic approach to cardiovascular risk management in the Chinese AF population

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly